Literature DB >> 9088749

Epidemiology and prevention of pertussis.

Q He1, J Mertsola.   

Abstract

Pertussis continues to be a common cause of morbidity and mortality in unimmunized young children. In immunized populations, the disease remains endemic and epidemic. Reports of pertussis infection in older children and adults are increasing, and the data indicate that lifelong immunity from either pertussis immunization or childhood pertussis does not exist, which stresses the importance of continued booster immunization in this population. The less reactogenic acellular pertussis vaccines, which may provide protection equal to or even better than that provided by currently used whole-cell vaccines, seem to be suitable not only for primary immunization but also for boostering in all age groups. This review focuses on some recent developments in the epidemiology and prevention of pertussis infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9088749     DOI: 10.1097/00008480-199702000-00005

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  3 in total

Review 1.  Reduced-antigen combined diphtheria-tetanus-acellular pertussis vaccine (Boostrix).

Authors:  Therese M Chapman; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  External quality assessment for molecular detection of Bordetella pertussis in European laboratories.

Authors:  G Muyldermans; O Soetens; M Antoine; S Bruisten; B Vincart; F Doucet-Populaire; N K Fry; P Olcén; J M Scheftel; J M Senterre; A van der Zee; M Riffelmann; D Piérard; S Lauwers
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

3.  Rapid typing of Bordetella pertussis pertussis toxin gene variants by LightCycler real-time PCR and fluorescence resonance energy transfer hybridization probe melting curve analysis.

Authors:  Johanna Mäkinen; Jussi Mertsola; Matti K Viljanen; Heikki Arvilommi; Qiushui He
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.